The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some current weight loss approaches, retatrutide appears to provide a more substantial decrease in body weight and improve metabolic function, p